VRT-043198

• Description:

  VRT-043198, the agent metabolite of VX-765 (Belnacasan), is a potent, selective and blood-brain barrier permeable inhibitor of interleukin-converting enzyme/caspase-1 subfamily caspases. VRT-043198 exhibits Ki values of 0.8 nM and 0.6 nM for ICE/caspase-1 and caspase-4, respectively[1].

• UNSPSC:

  12352005

• Target:

  Caspase; Drug Metabolite

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/vrt-043198.html

• Purity:

  98.89

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(N[C@H](C=O)CC(O)=O)[C@H]1N(C([C@H](C(C)(C)C)NC(C2=CC=C(N)C(Cl)=C2)=O)=O)CCC1

• Molecular Formula:

  C22H29ClN4O6

• Molecular Weight:

  480.94

• References & Citations:

  [1]Woods Wannamaker, et al. (S) -1- ((S) -2-{[1- (4-amino-3-chloro-phenyl) -methanoyl]-amino}-3,3-dimethyl-butanoyl) -pyrrolidine-2-carboxylic acid ((2R,3S) -2-ethoxy-5-oxo-tetrahydro-furan-3-yl) -amide (VX-765), an orally available selective interleukin (IL) -converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007 May;321 (2) :509-16.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Caspase 1; Caspase 4

• CAS Number:

  [244133-31-1]